abiraterone has been researched along with 3beta-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene in 21 studies
| Studies (abiraterone) | Trials (abiraterone) | Recent Studies (post-2010) (abiraterone) | Studies (3beta-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene) | Trials (3beta-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene) | Recent Studies (post-2010) (3beta-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene) |
|---|---|---|---|---|---|
| 942 | 97 | 854 | 50 | 2 | 44 |
| Protein | Taxonomy | abiraterone (IC50) | 3beta-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene (IC50) |
|---|---|---|---|
| Steroid 17-alpha-hydroxylase/17,20 lyase | Homo sapiens (human) | 0.253 | |
| Steroid 21-hydroxylase | Homo sapiens (human) | 0.1626 | |
| Androgen receptor | Homo sapiens (human) | 1.108 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 18 (85.71) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Brodie, AM; Chopra, P; Farquhar, R; Gediya, LK; Guo, Z; Handratta, VD; Kataria, R; Newman, D; Njar, VC; Qiu, Y; Vasaitis, TS | 1 |
| Brodie, AM; Njar, VC | 1 |
| Kwegyir-Afful, AK; Martin, MS; Njar, VC; Purushottamachar, P; Ramalingam, S; Ramamurthy, VP | 1 |
| López, Ó; Merino-Montiel, P; Meza-Reyes, S; Montiel-Smith, S; Padrón, JM; Romero-Hernández, LL; Vega-Baez, JL | 1 |
| Aubé, J; Fehl, C; Li, K; Scott, EE; Vogt, CD; Yadav, R | 1 |
| Cao, C; Chen, Y; Li, X; Yan, G; Yu, J; Zhang, L; Zhou, F; Zhou, P | 1 |
| Lu, Z; Luo, X; Meng, X; Wang, A; Wang, Y; Yang, Y | 1 |
| Ates-Alagoz, Z; Brodie, AM; Bruno, RD; Gediya, LK; Godbole, AM; Njar, VC; Purushottamachar, P; Vasaitis, TS | 1 |
| Cinar, B; Collak, FK; Soifer, HS; Souleimanian, N; Stein, CA; Voskresenskiy, AM; Wu, S | 1 |
| DeVore, NM; Scott, EE | 1 |
| Courtney, KD; Taplin, ME | 1 |
| Bambury, RM; Rathkopf, DE | 1 |
| Abbott, DH; Bird, IM | 1 |
| Bogner, J; Hickson, I; Romer, T; Yurlova, L; Zolghadr, K | 1 |
| Dick, B; Hartmann, RW; Hu, Q; Pandey, AV; Udhane, SS | 1 |
| Bubley, GJ; Fiorillo, M; Heath, EI; McKay, RR; Montgomery, RB; Roberts, J; Taplin, ME; Werner, L | 1 |
| Borgmann, H; Ost, P; Ploussard, G; Surcel, CI; Tsaur, I | 1 |
| Bansal, S; Lau, AJ; Wong, SY; Yip, CKY | 1 |
| Archakov, A; Gilep, A; Kuzikov, A; Masamrekh, R; Shkel, T; Shumyantseva, V; Strushkevich, N; Toropygin, I; Usanov, S; Veselovsky, A | 1 |
| Hu, J; Shen, H; Song, D; Sun, Z; Wang, Y; Wen, X; Xu, S; Xu, Y; Zhang, J | 1 |
| Latysheva, AS; Misharin, AY; Morozevich, GE; Novikov, RA; Pokrovsky, VS; Scherbakov, KA; Timofeev, VP; Tkachev, YV; Veselovsky, AV; Zolottsev, VA | 1 |
3 review(s) available for abiraterone and 3beta-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene
| Article | Year |
|---|---|
The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.
Topics: Androgen Antagonists; Androgens; Androstadienes; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Benzimidazoles; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Thiohydantoins | 2012 |
Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.
Topics: Androgen Receptor Antagonists; Androstadienes; Androstenes; Benzamides; Benzimidazoles; Humans; Male; Naphthalenes; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyrazoles; Receptors, Androgen; Thiohydantoins; Triazoles | 2016 |
The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
Topics: Adrenal Hyperplasia, Congenital; Androstadienes; Androstenes; Antineoplastic Agents; Benzimidazoles; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Humans; Hydrocortisone; Imidazoles; Ketoconazole; Male; Naphthalenes; Prednisone; Prostate; Prostatic Neoplasms; Protective Factors; Steroid 17-alpha-Hydroxylase; Triazoles | 2016 |
18 other study(ies) available for abiraterone and 3beta-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene
| Article | Year |
|---|---|
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstadienes; Animals; Antineoplastic Agents; Azoles; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Humans; Isoenzymes; Male; Mice; Mice, SCID; Mutation; Prostatic Neoplasms; Pyrazines; Radioligand Assay; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Tissue Distribution; Transcription, Genetic; Transcriptional Activation; Xenograft Model Antitumor Assays | 2005 |
Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
Topics: Androgen Receptor Antagonists; Androstadienes; Benzimidazoles; Clinical Trials as Topic; Drug Discovery; Humans; Male; Molecular Structure; Molecular Targeted Therapy; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Tissue Distribution | 2015 |
Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.
Topics: | 2016 |
Synthesis of unprecedented steroidal spiro heterocycles as potential antiproliferative drugs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Heterocyclic Compounds; Humans; Models, Molecular; Molecular Structure; Spiro Compounds; Steroids; Structure-Activity Relationship | 2018 |
Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2.
Topics: Androstenes; Catalytic Domain; Cytochrome P-450 Enzyme Inhibitors; Drug Design; Humans; Molecular Docking Simulation; Steroid 17-alpha-Hydroxylase; Steroid 21-Hydroxylase | 2018 |
Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Male; Models, Molecular; Molecular Structure; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
Topics: Androgen Receptor Antagonists; Cell Line, Tumor; Cell Proliferation; Hormones; Humans; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2022 |
Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.
Topics: Androstadienes; Androstenes; Androstenols; Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase III as Topic; Drug Combinations; Estradiol; Humans; Male; Mice; Mice, SCID; Norethindrone; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Testosterone; Xenograft Model Antitumor Assays | 2011 |
Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Substitution; Androstadienes; Androstenes; Androstenols; Benzimidazoles; Cell Cycle Proteins; Cell Line, Tumor; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Male; Mutation, Missense; Phosphoproteins; Prostatic Neoplasms; Protein Binding; Receptors, Androgen; Steroid 17-alpha-Hydroxylase | 2012 |
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
Topics: Androstadienes; Androstenes; Androstenols; Antineoplastic Agents; Benzimidazoles; Biocatalysis; Catalytic Domain; Crystallography, X-Ray; Humans; Hydrogen Bonding; Ligands; Male; Models, Molecular; Prostatic Neoplasms; Protein Conformation; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; United States; United States Food and Drug Administration | 2012 |
The fluorescent two-hybrid assay for live-cell profiling of androgen receptor modulators.
Topics: Androgen Antagonists; Androgens; Androstadienes; Androstenes; Anilides; Animals; Benzamides; Benzimidazoles; Biological Assay; Cell Line; Cricetinae; Dihydrotestosterone; Flutamide; HEK293 Cells; Humans; Male; Microscopy, Fluorescence; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Transcription Factors; Two-Hybrid System Techniques | 2017 |
Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.
Topics: Adrenal Glands; Androgens; Androstadienes; Androstenes; Antineoplastic Agents; Benzimidazoles; Cell Line; Dose-Response Relationship, Drug; Humans; Imidazoles; Male; Naphthalenes; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2016 |
Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer.
Topics: Aged; Androstadienes; Androstenes; Benzamides; Benzimidazoles; Drug Therapy; Humans; Kallikreins; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Treatment Outcome | 2017 |
AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked?
Topics: Androgen Receptor Antagonists; Androstadienes; Androstenes; Antineoplastic Agents; Benzamides; Benzimidazoles; Clinical Trials, Phase III as Topic; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Receptors, Androgen; RNA Splice Sites; RNA, Messenger; Treatment Outcome | 2018 |
Identification of Galeterone and Abiraterone as Inhibitors of Dehydroepiandrosterone Sulfonation Catalyzed by Human Hepatic Cytosol, SULT2A1, SULT2B1b, and SULT1E1.
Topics: Adolescent; Adult; Aged; Androstadienes; Androstenes; Benzimidazoles; Cytosol; Dehydroepiandrosterone; Female; Humans; Kinetics; Liver; Male; Middle Aged; Sulfotransferases; Young Adult | 2018 |
Interaction of 17α-hydroxylase, 17(20)-lyase (CYP17A1) inhibitors - abiraterone and galeterone - with human sterol 14α-demethylase (CYP51A1).
Topics: Androstadienes; Androstenes; Benzimidazoles; Catalysis; Catalytic Domain; Cytochrome P-450 Enzyme Inhibitors; Electrochemical Techniques; Humans; Molecular Docking Simulation; Steroid 17-alpha-Hydroxylase; Sterol 14-Demethylase | 2018 |
Comparative study of the binding mode between cytochrome P450 17A1 and prostate cancer drugs in the absence of haem iron.
Topics: Androstadienes; Androstenes; Antineoplastic Agents; Benzimidazoles; Binding Sites; Catalytic Domain; Cytochrome P-450 CYP1A1; Heme; Humans; Hydrophobic and Hydrophilic Interactions; Iron; Male; Molecular Docking Simulation; Prostatic Neoplasms; Protein Conformation, alpha-Helical | 2019 |
New steroidal oxazolines, benzoxazoles and benzimidazoles related to abiraterone and galeterone.
Topics: Androstadienes; Androstenes; Antineoplastic Agents; Benzimidazoles; Benzoxazoles; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Conformation; Oxazoles; PC-3 Cells; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |